Search Results 1181-1190 of 1370 for ✔[광고텔레:SEOGOT] 구글야동사이트홍보 장집홍보 대포유심삽니다 게임핵 선불유심팝니다 해외선물솔루션홍보 상위노출대행 신용카드현금화하는법 010실명인증구입 슬롯커뮤니티홍보✔

1. A Study to Collect Clinical Outcomes of Anatomic and Reverse Total Shoulder Arthroplasty

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

2. BT – L-CsA – 301 – SLT: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Efficacy and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Chronic Lung Allograft Syndrome / Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation - Mayo Clinic

   ... Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Chronic Lung Allograft ...

3. Treatment of IgG4-Related Disease With Revlimid and Rituximab - Mayo Clinic

   About this study. Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite ...

4. Jason Howland | Mayo Clinic News Network - Page 29 of 38

   A former TV news anchor and reporter for KAAL-TV, the ABC affiliate in Rochester, Minnesota, he has nearly 30 years of broadcast journalism experience. Jason ...

5. Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) - Mayo Clinic

   The purpose of this study is to characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell ...

6. A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations - Mayo Clinic

   The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable ...

7. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   Treatment with panitumumab may interfere with the ability of tumor cells to grow and spread. Some tumors need growth factors to keep growing. Growth factor ...

8. Joel Streed | Mayo Clinic News Network - Page 155 of 170

   Marlow and Fran Cowan returned to Mayo Clinic campus in Rochester this week. You likely remember them as the couple whose piano duet became a YouTube[...] By ...

9. Deb Balzer | Mayo Clinic News Network - Page 10 of 71

   Graves' disease is an autoimmune disorder that triggers the thyroid gland to produce more thyroid hormones than the body needs. It's the most common cause[...].

10. IMPRoving Outcomes in Vascular DisEase- Aortic Dissection - Mayo Clinic

    About this study. The purpose of this study is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a ...